Patents Assigned to Array Biopharma Inc.
  • PROTEIN TYROSINE PHOSPHATASE INHIBITORS
    Publication number: 20250066357
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases.
    Type: Application
    Filed: November 13, 2024
    Publication date: February 27, 2025
    Applicant: Array BioPharma Inc.
    Inventors: James Francis BLAKE, Mark Laurence BOYS, Mark Joseph CHICARELLI, Adam Wade COOK, Mohamed S.A. ELSAYED, Jay Bradford FELL, John Peter FISCHER, Ronald Jay HINKLIN, Oren Teague MCNULTY, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Christina Elizabeth WONG
  • Pharmaceutical composition
    Patent number: 12220403
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Grant
    Filed: October 10, 2023
    Date of Patent: February 11, 2025
    Assignees: AstraZeneca AB, Array BioPharma, Inc.
    Inventors: Nicola Frances Bateman, Paul Richard Gellert, Kathryn Jane Hill
  • CRYSTALLINE FORM OF N-(2-CHLORO-3-((5-CHLORO-3-METHYL-4-OXO-3,4-DIHYDROQUINAZOLIN-6-YL)AMINO)-4-FLUOROPHENYL)-3-FLUOROAZETIDINE-1-SULFONAMIDE
    Publication number: 20250011304
    Abstract: This invention relates to a crystalline form of N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide, pharmaceutical compositions comprising said crystalline form, and methods of using said crystalline form in the treatment of BRAF-associated diseases and disorders, such as BRAF-associated tumors.
    Type: Application
    Filed: December 2, 2022
    Publication date: January 9, 2025
    Applicant: Array BioPharma Inc.
    Inventor: Connor James COWDREY
  • Protein tyrosine phosphatase inhibitors
    Patent number: 12187721
    Abstract: Compounds of Formula Ia or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: January 7, 2025
    Assignee: Array BioPharma Inc.
    Inventors: James Francis Blake, Mark Laurence Boys, Mark Joseph Chicarelli, Adam Wade Cook, Mohamed S. A. Elsayed, Jay Bradford Fell, John Peter Fischer, Ronald Jay Hinklin, Oren Teague Mcnulty, Macedonio J. Mejia, Martha E. Rodriguez, Christina Elizabeth Wong
  • Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
    Patent number: 12180207
    Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which Ring A, Ring B, Ring C, R1, R2, L, Y, and W have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: December 31, 2024
    Assignee: Array Biopharma Inc.
    Inventors: James F. Blake, David A. Moreno, Li Ren, Tony P. Tang, Shane M. Walls
  • N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
    Patent number: 12171739
    Abstract: This invention provides compounds of Formula I wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
    Type: Grant
    Filed: September 8, 2022
    Date of Patent: December 24, 2024
    Assignee: ARRAY BIOPHARMA INC.
    Inventors: Joseph P. Lyssikatos, Julie Marie Hicks, Fredrik P. Marmsater, Qian Zhao
  • CRYSTALLINE FORM OF A SHP2 INHIBITOR
    Publication number: 20240190843
    Abstract: This Invention relates to a hemihydrate crystalline form of (S)-1?-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4?-piperidin]-1-amine free base (Form 1). The invention also relates to pharmaceutical compositions comprising this crystalline form, and to methods of using the crystalline form and such compositions for the treatment of abnormal cell growth, such as cancer, in a mammal.
    Type: Application
    Filed: March 30, 2022
    Publication date: June 13, 2024
    Applicant: Array BioPharma Inc.
    Inventors: Katie Keaton BROWN, Aaron Keith GOODWIN
  • Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
    Patent number: 11998545
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: June 27, 2023
    Date of Patent: June 4, 2024
    Assignee: Array Biopharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Tony P. Tang, Li Ren
  • PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES
    Publication number: 20240174666
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.
    Type: Application
    Filed: August 29, 2023
    Publication date: May 30, 2024
    Applicant: Array BioPharma Inc.
    Inventors: Ronald Jay Hinklin, Shelley Allen, Patrick Michael Doerner Barbour, Adam Wade Cook, Joshua Ryan Dahlke, John Joseph Gaudino, Ellen Ruth Laird, Oren Teague McNulty, Qian Zhao
  • Fused heterocyclic compounds as RET kinase inhibitors
    Patent number: 11964988
    Abstract: Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: April 23, 2024
    Assignee: ARRAY BIOPHARMA INC.
    Inventors: James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Dean Kahn, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L McKenney, Andrew T. Metcalf, David A. Moreno, Brett Prigaro, Ginelle A. Ramann, Li Ren, Shane M. Walls, Hailong Zhang
  • KRas G12D inhibitors
    Patent number: 11964989
    Abstract: Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 20, 2022
    Date of Patent: April 23, 2024
    Assignees: Mirati Therapeutics, Inc., Array BioPharma Inc.
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • HER2 MUTATION INHIBITORS
    Publication number: 20240124474
    Abstract: This invention relates to compounds of Formula (I): and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
    Type: Application
    Filed: November 1, 2023
    Publication date: April 18, 2024
    Applicant: Array BioPharma Inc.
    Inventors: Mark Laurence BOYS, Bryan Daniel ELLIS, John Joseph GAUDINO, Erik James HICKEN, Ellen Ruth LAIRD, Nicholas Charles LAZZARA, Bradley Jon NEWHOUSE, Spencer Phillip PAJK
  • PROTEIN TYROSINE PHOSPHATASE INHIBITORS
    Publication number: 20240124453
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: November 17, 2023
    Publication date: April 18, 2024
    Applicant: Array BioPharma Inc.
    Inventors: James Francis BLAKE, Mark Laurence BOYS, Mark Joseph CHICARELLI, Adam Wade COOK, Mohamed S. A. ELSAYED, Jay Bradford FELL, John P. FISCHER, Ronald Jay HINKLIN, Yutong JIANG, Oren Teague MCNULTY, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Christina Elizabeth WONG
  • KRas G12C inhibitors
    Patent number: 11932633
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: March 19, 2024
    Assignees: Mirati Therapeutics, Inc., Array Biopharma Inc.
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, James F. Blake, Mark Joseph Chicarelli, Jay Bradford Fell, John P. Fischer, Erik James Hicken, Pavel Savechenkov, Tony Tang, Guy P. A. Vigers, Henry J. Zecca
  • Protein tyrosine phosphatase inhibitors
    Patent number: 11884664
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: January 30, 2024
    Assignee: Array BioPharma Inc.
    Inventors: James Francis Blake, Mark Laurence Boys, Mark Joseph Chicarelli, Adam Wade Cook, Mohamed S. A. Elsayed, Jay Bradford Fell, John P. Fischer, Ronald Jay Hinklin, Yutong Jiang, Oren Teague McNulty, Macedonio J. Mejia, Martha E. Rodriguez, Christina Elizabeth Wong
  • Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors
    Patent number: 11851434
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: December 26, 2023
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, James F. Blake, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, David A. Moreno, Li Ren, Shane M. Walls
  • Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
    Patent number: 11834453
    Abstract: This invention relates to compounds of Formula (I): and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: December 5, 2023
    Assignee: Array BioPharma Inc.
    Inventors: Mark Laurence Boys, Bryan Daniel Ellis, John Joseph Gaudino, Erik James Hicken, Ellen Ruth Laird, Nicholas Charles Lazzara, Bradley Jon Newhouse, Spencer Phillip Pajk
  • Pharmaceutical composition
    Patent number: 11813246
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Grant
    Filed: May 6, 2021
    Date of Patent: November 14, 2023
    Assignees: AstraZeneca AB, Array BioPharma, Inc.
    Inventors: Nicola Frances Bateman, Paul Richard Gellert, Kathryn Jane Hill
  • Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
    Patent number: 11807651
    Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: November 7, 2023
    Assignees: Loxo Oncology Inc., Array BioPharma Inc.
    Inventors: Charles Todd Eary, Stacey Spencer, Zack Crane, Katelyn Chando, Sylvie Asselin, Weidong Liu, Mike Welch, Adam Cook, Gabrielle R. Kolakowski, Andrew T. Metcalf, David A. Moreno, Tony P. Tang
  • Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases
    Patent number: 11780835
    Abstract: Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: October 10, 2023
    Assignee: Array BioPharma Inc.
    Inventors: Ronald Jay Hinklin, Shelley Allen, Patrick Barbour, Adam Cook, Joshua Dahlke, John Gaudino, Ellen Laird, Oren T. McNulty, Qian Zhao